IgA Nephropathy Market Size in the 7MM and China was ~USD 190 million in 2021

IgA Nephropathy market report provides current treatment practices, emerging drugs, and their market share of the individual therapies, current and forecasted IgA Nephropathy market size from 2019 to 2032 segmented by eight major markets. The report also covers current IgA Nephropathy symptoms treatment practice/algorithm and unmet medical needs to curate the best opportunities. It assesses the underlying potential of the market.

"IgA Nephropathy market is expected to experience a growth boost mainly attributed to increased prevalence, anticipated launch of novel therapies, and also the key pharmaceuticals like Novartis, Calliditas Therapeutics, Chinook Therapeutics are setting foot in the IgA Nephropathy market domain"

Key takeaways from the IgA Nephropathy Market Research Report

• The total IgA Nephropathy associated prevalent cases in the 7MM and China countries was ~1.7 million in 2021.

• The IgA Nephropathy market size in the seven major markets and China was ~USD 190 million in 2021, which is expected to grow by 2032.

• IgA Nephropathy therapeutics market companies include Calliditas Therapeutics AB, Travere Therapeutics, Inc., Omeros Corporation, Novartis Pharmaceuticals, Chinook Therapeutics, Inc., Vera Therapeutics, Inc., Otsuka Pharmaceutical, and others.

• IgA Nephropathy Pipeline Therapies includes Omega-3 fatty acid ethylester90, Budesonide, Tacrolimus, BION-1301 Single Dose, NEFECON, Blisibimod, Atacicept, RC18 160mg, LNP023, and others.

To discover which therapies are expected to grab the major IgA Nephropathy Market share, click here for IgA Nephropathy Market Research Report @ https://www.delveinsight.com/sample-request/iga-nephropathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

IgA Nephropathy Overview
IgAN is an autoimmune disease that attacks the kidneys. It affects blood filtration in the small blood vessels of the kidneys. It occurs when an abnormal protein damages the filtering unit (glomerulus) inside the kidneys. Conventional major treatments to manage IgAN include ACE inhibitors (angiotensin-converting enzyme inhibitors) and ARBs (angiotensin II receptor blockers), to manage symptoms like high blood pressure, etc. Other treatments include corticosteroids, to slow the progression of the disease, and other immunesuppressants like MMF, cyclophosphamide, etc.

Latest Developmental Activities in the IgA Nephropathy Treatment Landscape

• TARPEYO (budesonide) delayed release capsules, is the first and only FDA approved drug for the treatment of IgAN. It is indicated for IgAN patients, who at risk of rapid disease progression, generally a urine protein-to-creatinine ratio (UPCR) ≥ 1.5 g/g. It was approved by the US FDA in December 2021, under accelerated approval pathway, recognizing the urgent need for safe and efficacious therapies.

• In March 2022, Travere Therapeutics submitted the NDA application for accelerated approval and is expecting the acceptance of application and PUFDA in May 2022.

• In January 2022, Calliditas Therapeutics announced the commercial availability and initial sales of Tarpeyo (budesonide), the first and only FDA approved treatment for IgA nephropathy, in the US. It is indicated for reduction of proteinuria in adults with primary IgA nephropathy at risk of rapid disease progression, generally considered a urine protein-to-creatinine ratio (UPCR) ≥1.5g/g.

• In December 2021, TARPEYO (budesonide) delayed release capsules was approved by US FDA for the treatment of IgAN patients, at risk of rapid disease progression, generally a urine protein-to-creatinine ratio (UPCR) ≥1.5g/g. This is the first and only treatment indicated to reduce proteinuria in adults with primary IgAN. However, there are no targeted approved therapies for IgAN patients currently available, although several new molecules are under investigation.

IgA Nephropathy Epidemiology Segmentation in the 7MM

• Total IgA Nephropathy Prevalent cases
• IgA Nephropathy Gender-specific cases
• IgA Nephropathy Age-specific cases

Download the report to understand which factors are driving IgA Nephropathy epidemiology trends, click here for IgA Nephropathy epidemiology segmentation @ https://www.delveinsight.com/sample-request/iga-nephropathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

IgA Nephropathy Emerging Drugs

Tarpeyo: Calliditas Therapeutics AB

Tarpeyo (developed under the project name Nefecon) is a patented oral formulation of a potent and well-known active substance- budesonide for targeted release. The formulation is designed to deliver the drug to the Peyer's patch region of the lower small intestine, where the disease originates, as per the predominant pathogenesis models. Tarpeyo is derived from the TARGIT technology, which allows the substance to pass through the stomach and intestine without being absorbed and released in a pulse-like fashion only when it reaches the lower small intestine. In addition to its potent local effect, another advantage of using this active substance is its very low bioavailability, i.e., around 90% of it is inactivated in the liver before it reaches the systemic circulation. This means that a high concentration can be applied locally where needed but with only very limited systemic exposure and side effects.

Sparsentan: Travere Therapeutics, Inc

Sparsentan is a first-in-class, orally active, single-molecule that functions as a high-affinity dual-acting antagonist of both endothelin type A (ETA) and angiotensin II subtype 1 (AT1) receptors which are associated with kidney disease progression. Endothelin I and angiotensin II leads to decline in kidney function by contributing to inflammation and fibrosis in the kidney, changes to the shape of podocytes, podocyte loss, and increased permeability of the glomerular filtration barrier. Endothelin I and angiotensin II are also vasoconstrictive, meaning they cause a narrowing of blood vessels and an increase in pressure in the glomeruli.

IgA Nephropathy Market Outlook

DelveInsight estimates the market size for IgA Nephropathy was found to be USD 109.3 million in 2020 in the 7MM. Also, the market size of IgA Nephropathy is anticipated to increase during the study period, 2018-2030. Current IgA Nephropathy treatment options include corticosteroids, tonsillectomy, drugs like Aliskiren, Cyclosporine, and Mycophenolate Mofetil (immunosuppressive agent) as medications that can slow the progress of the disease and help manage symptoms such as high blood pressure, protein in the urine, and swelling. Although several new molecules are under investigation, there is still an absence of disease-specific treatment for IgA Nephropathy patients.

To learn more about the IgA Nephropathy FDA-approved drugs, click here for IgA Nephropathy Emerging Drugs & Companies, Know about IgA Nephropathy Treatment Market @ https://www.delveinsight.com/sample-request/iga-nephropathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

IgA Nephropathy Pipeline Therapies and Key Companies

• Iptacopan: Novartis
• Nefecon: Calliditas Therapeutics
• Atrasentan: Chinook Therapeutics
• Sparsentan: Travere Therapeutics Inc.
• Narsoplimab: Omeros

Scope of the IgA Nephropathy Market Research Report

• Coverage- 7MM

• IgA Nephropathy Companies- Calliditas Therapeutics AB, Travere Therapeutics, Inc., Omeros Corporation, Novartis Pharmaceuticals, Chinook Therapeutics, Inc., Vera Therapeutics, Inc., Otsuka Pharmaceutical, and others.

• IgA Nephropathy Pipeline Therapies- Omega-3 fatty acid ethylester90, Budesonide, Tacrolimus, BION-1301 Single Dose, NEFECON, Blisibimod, Atacicept, RC18 160mg, LNP023, and others.

• IgA Nephropathy Market Dynamics: IgA Nephropathy Market Drivers and Barriers

• IgA Nephropathy Market Access and Reimbursement

IgA Nephropathy Market: Drivers and Barriers

A robust pipeline of novel potential therapies as well as the discovery of new pathogenic mechanisms serves as major factors for IgA Nephropathy market growth in the coming years. Increased prevalence, development of novel biomarkers, strategic partnerships among active players, and the anticipated launch of novel therapies during the forecast period also attribute to the expected surge in the IgA Nephropathy market. Now, the unreported and undiagnosed IgA Nephropathy cases, lack of in-depth understanding of the disease pathogenesis, challenges in drug development like low recruitment numbers are several IgA Nephropathy market setbacks that can hold back the IgAN market. Heterogeneous clinical presentation and the variation in the prevalence of IgA Nephropathy are also considered some of the potential drawbacks.

To discover more about IgA Nephropathy Market Drugs in development, click here for IgA Nephropathy Market Dynamics and IgA Nephropathy Market Drivers & Barriers @ https://www.delveinsight.com/sample-request/iga-nephropathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Key Insights
2. Report Introduction
3. IgA Nephropathy Market Overview at a Glance
4. Executive Summary of IgA Nephropathy
5. Disease Background and Overview
6. Epidemiology and Patient Population
7. Patient Journey
8. Emerging Therapies
9. IgA Nephropathy: 7MM + China Market Analysis
10. SWOT Analysis
11. Unmet Needs
12. KOL Views
13. Market Access and Reimbursement
14. Appendix
15. DelveInsight Capabilities
16. Disclaimer
17. About DelveInsight

To read more about the IgA Nephropathy Patient Population of the report, click here for IgA Nephropathy Unmet Needs and Patient Journey @ https://www.delveinsight.com/sample-request/iga-nephropathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

This release was published on openPR.